Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (1)
Austria (1)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
The Phillippines (1)
United Kingdom (3)
Vietnam (2)
Innovating to meet patient needs
STADA’s Specialty Pharmaceuticals segment delivers innovative, competitive medicines used to improve the lives and clinical outcomes of patients worldwide who live with chronic, complex or rare conditions.
Specialty pharmaceuticals typically have complex characteristics in terms of how they are manufactured, prescribed, distributed and administered and may include novel formulations and combinations, as well as new uses that add value to known active ingredients. Specialty medicines are integral to STADA’s purpose of Caring for People’s Health as they can address unmet medical needs and relieve financial pressures across healthcare systems.
Our Specialty Pharmaceuticals portfolio consists of a diverse set of biosimilars as well as innovative products within complex therapeutic areas.
By continuously expanding our Specialty pipeline of medicines, growing our expertise and developing trusted partnerships, we continue to strengthen the performance of our Specialty Pharmaceuticals business.
What therapeutic areas are we focusing on?
We prioritize partnerships that help us in Caring for People’s Health as a Trusted Partner. We currently offer high-quality medicines within the following therapeutic areas:
Nephrology
Epoetin zeta (biosimilar) – for symptomatic anemia associated with chronic renal failure.
Innovative targeted-release formulation of budesonide used to treat primary immunoglobulin A nephropathy (IgAN).
Neurology
Device-driven combination of levodopa, carbidopa and entacapone – late-stage Parkinson’s.
Oncology
Pegfilgrastim (biosimilar) – cancer patients with neutropenia. Bevacizumab (biosimilar) – cancers.
"STADA‘s growing Specialty Pharmaceuticals business is committed to becoming the partner of choice for payers, physicians and patients by ensuring people living with chronic conditions have access to life-altering, high-quality and affordable treatments."
BRYAN KIM
Executive Vice President Global Specialty Pharmaceuticals
